Allergan Inc. (AGN)

AGN (NYSE:Drugs)
$98.50
neg -2.91
-2.87%
Today's Range: 98.17 - 101.40 | AGN Avg Daily Volume: 1,745,200
Last Update: 05/20/13 - 4:00 PM EDT
Volume: 2,585,727
YTD Performance: 7.38%
Open: $101.40
Previous Close: $101.41
52 Week Range: $81.28 - $116.45
Oustanding Shares: 296,400,416
Market Cap: 30,057,966,187
6-Month Chart
TheStreet Ratings Grade for AGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 14 13 13 14
Moderate Buy 2 3 3 3
Hold 8 8 8 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.75 1.77 1.77 1.69
Latest Dividend: 0.05
Latest Dividend Yield: 0.20%
Dividend Ex-Date: 05/21/13
Price Earnings Ratio: 27.19
Price Earnings Comparisons:
AGN Sector Avg. S&P 500
27.19 35.20 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-8.86% 10.95% 68.66%
GROWTH 12 Mo 3 Yr CAGR
Revenue 7.10 0.29 0.09
Net Income 0.00 0.77 0.21
EPS 18.90 0.78 0.21
Earnings for AGN:
EBITDA 1.89B
Revenue 5.81B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $1.20 $1.21 $4.75 $5.48
Number of Analysts 15 15 19 18
High Estimate $1.25 $1.26 $4.88 $5.84
Low Estimate $1.18 $1.18 $4.71 $5.28
Prior Year $1.07 $1.06 $4.14 $4.75
Growth Rate (Year over Year) 12.09% 14.53% 14.80% 15.30%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
jeffreyswaim
jeffreyswaim: @jimcramer $AGN ready for a comeback? Or still room to fall after Q1's call?
6 hours ago from web
DDNotesMaker
DDNotesMaker: Check out $AGN on http://t.co/3MIssHD6Ji
14 hours ago from DDNotesMakerPost
DDNotesMaker
DDNotesMaker: Check out $AGN on http://t.co/3MIssHD6Ji
14 hours ago from DDNotesMakerPost
DDNotesMaker
DDNotesMaker: Check out $AGN on http://t.co/3MIssHD6Ji
15 hours ago from DDNotesMakerPost
tymorapro
tymorapro: $AGN: At/Below 200DaySMA 1DyLo50%R[98.65,6m,0.15offLo]:3M, lm:-4, DyRng:2.90, 0NearLo, tf:21, ch:-2.8%, 1WkLo-; TLM:98; cl-op-
15 hours ago from tymoraPRO tradeScan
DDNotesMaker
DDNotesMaker: Check out $AGN on http://t.co/3MIssHD6Ji
15 hours ago from DDNotesMakerPost
DDNotesMaker
DDNotesMaker: Check out $AGN on http://t.co/3MIssHD6Ji
15 hours ago from DDNotesMakerPost
DDNotesMaker
DDNotesMaker: Check out $AGN on http://t.co/3MIssHD6Ji
15 hours ago from DDNotesMakerPost
Arthur_i_Brown
Arthur_i_Brown: @SeemaCnbc @CourtReagan @GCGodfrey 2day: called out of $FCX and $OWW so I used the proceeds 2buy a bit of $WWAV & a lot of $AGN. Soy&botox.
16 hours ago from web
jgre910
jgre910: 99.39 for 3000 $AGN
19 hours ago from web

'Mad Money' Uncovered: Allergan

By

Jim Cramer

 | May 8, 2013 | 6:00 AM EDT

Jim Cramer looks at the overdone selloff in Allergan with 'Mad Money' Research Director Nicole Urken.

It's Pipeline That Matters Most

By

Jim Cramer

 | May 1, 2013 | 12:49 PM EDT

Focusing on near-term drug stock earnings is the wrong move.

Cramer Talks Abbott & Glaxo

By

Jim Cramer

 | Apr 17, 2013 | 3:15 PM EDT

TheStreet's Jim Cramer says Abbott Labs will benefit from growth in emerging markets and Glaxo will benefit from a "huge pipeline of approvals." The Action Alerts Plus portfolio recently bought Glaxo shares and added to their position in Abbott Labs.

updateLeerink Healthcare Conf.

Feb 14, 2013 | 6:34 AM EST

Leerink Swann Global Healthcare Conference (Day 2 of 2) - 02/13/13 - 02/14/13 New York, NY

bullishAllergan price target increased at Citigroup

Feb 7, 2013 | 7:57 AM EST

AGN price target raised to $124, Citigroup said. Core franchises continue to deliver double digit growth. Buy rating. 

Allergan: Invest In This Biopharma

By

Jim Cramer

 | Feb 6, 2013 | 11:26 AM EST

Jim Cramer and his research associate Nicole Urken discuss Allergan's pipeline.

Before the Bell: Feb. 6

By

David Peltier

 | Feb 6, 2013 | 8:13 AM EST

Portfolio manager David Peltier previews Wednesday's trading action.

bullishAllergan numbers raised at Jefferies

Feb 6, 2013 | 8:00 AM EST

Shares of AGN now seen reaching $100, Jefferies said. Estimates also raised on resiliency of model in the fourth quarter. Hold rating.

bullishAllergan upgraded at JMP

Feb 6, 2013 | 7:42 AM EST

AGN was upgraded from Market Perform to Outperform, JMP Securities said. $135 price target. Company is seeing higher demand for Botox. 

Should Blaze Ahead This Year

By

Jim Cramer

 | Feb 6, 2013 | 6:21 AM EST

Remember when I said you want to buy a pullback? Take a good, long look at these two stellar names.

Columnist Conversation / Market Updates

Corporate Taxes...
By

Doug Kass

 | May 20, 2013 | 5:11 PM EDT
Corp taxes as a % of national income just hit a record low, surpassing the previous record set in 1929!!!!!

Bed Bath and Beyond Breaking Down
By

Gary Morrow

 | May 20, 2013 | 3:53 PM EDT
Shares of BBBY are taking a damaging hit today. The stock has traded heavy all day following a valuation based down...
See more »

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.